Hepatitis C infection and thyrotoxic periodic paralysis: a novel use of an old drug

- Tran, Huy A., Reeves, Glenn E.

Disclosing hepatitis C infection within everyday contexts implications for accessing support and healthcare

- Hopwood, Max, Nakamura, Tamo, Treloar, Carla

Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: the LiveRLife study

- Marshall, A. D., Micallef, M., Harvey, P., Dunlop, A., Jauncey, M., Read, P., Collie, T., Dore, G. J., Grebely, J., Erratt, A., Telenta, J., Treloar, C., Everingham, H., Jones, S. C., Bath, N., How-Chow, D., Byrne, J.

Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective

- Tran, Huy A., Jones, Tracey L., Ianna, Elizabeth A., Foy, Aidan, Reeves, Glenn E. M.

The adjuvant role of thyroxine in the treatment of chronic hepatitis C infection

- Tran, H. A., Ianna, E. A., Jones, T. L., Reeves, G. E. M.

Hepatitis screening in Japanese individuals of working age and prejudice against infected persons in the workplace

- Sasaki, Nanae, Wada, Koji, Smith, Derek R., Wang, Guoquin, Ohta, Hiroshi, Shibuya, Akitaka

How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting

- Treloar, Carla, Rance, Jake, Loveday, Stuart, Micallef, Michelle, Thein, Hla-Hla, Alavi, Maryam, Marks, Pip, Jones, Ineke, Siriragavan, Sharmila, Tamaddoni, Mahshid, Abbott, P., Balcomb, Annie, Haber, Paul, van Beek, Ingrid, Dunlop, Adrian, Phung, Nghi, Weltman, Martin, Doab, Anna, Hazelwood, Sussan, Lam, Thao, Petersen, Jamieleigh, Sevehon, Alison, Taylor, Ann, Bath, Nicky, D'Aquino, Fiona, Evangelista, Lucia, Pollard, Emma, Wrightson, Julieanne, Day, Carolyn, Dore, Gregory, Grebely, Jason, Honey, Claire, Krahn, Murray, Lodge, Mike

Histopathologic findings of autoimmunity in thyroid, pituitary, and adrenal diseases in chronic hepatitis C postmortem cases

- Tran, Huy A., Reeves, Glenn E. M., Lyons, Tim J., Attia, John R.

Predictors of deferral of treatment for hepatitis C infection in Australian clinics

- Gidding, Heather F., Law, Matthew G., Amin, Janaki, MacDonald, Graeme A., Sasadeusz, Joe J., Levett-Jones, Tracy L., Strasser, Simone I., George, Jacob, Dore, Gregory J.

Chronic hepatitis B and C infection in children in New South Wales

- Nightingale, Scott, Stormon, Michael O., Day, Andrew S., Webber, Murray T., Ward, Kate A., O'Loughlin, Edward V.

The natural history of interferon-2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection

- Tran, H. A., Reeves, G. E. M., Jones, T. L.

Ongoing care and follow-up behavior of working age Japanese with hepatitis C virus

- Wada, Koji, Smith, Derek R., Eguchi, Hisashi

Hepatitis C caseload and models of care for rural GPs working in northern New South Wales

- Fraser, John, Alexander, C, Fisher, K

Peginterferon and ribavirin for hepatitis C (letter)

- Duggan, Anne E., Duggan, John M.

The natural history of interferon-α induced thyroiditis in chronic hepatitis c patients: a long term study

- Tran, Huy A., Jones, Tracey L., Ianna, Elizabeth A., Reeves, Glenn E. M.

Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: a nested case control study

- Tran, Huy A., Jones, Tracey L., Gibson, Robert, Reeves, Glenn E. M.

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

- Grebely, Jason, Dalgard, Olav, Amin, Janaki, Marks, Philippa S., Quiene, Sophie, Applegate, Tanya L., Weltman, Martin, Shaw, David, Dunlop, Adrian, Hellard, Margaret, Bruneau, Julie, Midgard, Håvard, Cunningham, Evan B., Hajarizadeh, Behzad, Foster, Graham R., Bruggmann, Philip, Conway, Brian, Backmund, Markus, Robaeys, Geert, Swan, Tracy

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

- Cunningham, Evan B., Hajarizadeh, Behzad, Swan, Tracy, Marks, Philippa S., Quiene, Sophie, Applegate, Tanya L., Weltman, Martin, Shaw, David, Dunlop, Adrian, Bruneau, Julie, Midgard, Håvard, Bourgeois, Stefan, Dalgard, Olav, Thurnheer, Maria Christine, Dore, Gregory J., Grebely, Jason, Amin, Janaki, Hellard, Margaret, Foster, Graham R., Bruggmann, Philip, Conway, Brian, Backmund, Markus, Robaeys, Geert

The effect of curing hepatitis C with direct-acting antiviral treatment on endothelial function

- Davis, Joshua S., Young, Melissa, Lennox, Sandra, Jones, Tracey, Piera, Kim, Pickles, Robert, Oakley, Stephen